GSK3:阿尔茨海默病治疗的潜在目标和悬而未决的问题
Jiahui Zhao1, Mengying Wei2,3, Minsong Guo2,4
1School of Basic Medical Sciences, Zhejiang Chinese Medical University, Hangzhou, China.
CNS neuroscience & therapeutics
|July 1, 2024
概括
糖原合成酶激酶-3 (GSK3) 在阿尔茨海默氏症 (AD) 中升高,导致关键病理,如陶酸化和粉样β形成. 抑制GSK3显示AD的治疗承诺,尽管需要特定的抑制剂.
科学领域:
- 神经科学是一个神经科学.
- 生物化学 生物化学
- 药理学 药理学是指药理学的学科.
背景情况:
- 阿尔茨海默病 (AD) 是一种神经退行性疾病,其特征是认知能力下降,粉样β (Aβ) 聚合和陶过酸化.
- 糖原合成酶激酶-3 (GSK3),包括GSK3α和GSK3β,因其在受影响的大脑中的表达增加而与AD病原发生有关.
研究的目的:
- 提供GSK3的结构,监管及其在阿尔茨海默病中的多方面的作用的全面概述.
- 分析GSK3过度激活和关键AD病理因素之间的关系.
- 审查支持GSK3抑制作为AD治疗策略的临床前证据.
主要方法:
- 文献综述和对GSK3结构,功能及其对AD的参与现有研究的分析.
- 检查GSK3对陶酸化,粉样蛋白前体蛋白 (APP) 裂变,神经炎症和氧化应激的影响.
- 关于研究GSK3抑制剂用于AD治疗的临床前研究的摘要.
主要成果:
- 过度激活GSK3会扰乱神经的发育和功能,直接促进陶酸化和调节APP裂变,从而导致Aβ形成.
- GSK3有助于神经炎症和氧化损伤,加剧AD病理.
- 临床前研究表明,抑制GSK3活性是AD的潜在治疗途径.
结论:
- GSK3是阿尔茨海默病的重要治疗点,影响多种病理途径.
- 开发用于临床使用的高特异性和亲和力驱动的GSK3抑制剂仍然存在挑战.
- 进一步的研究对于克服障碍和充分实现GSK3抑制在AD治疗中的潜力至关重要.
更多相关视频
09:33Quantitative 3D In Silico Modeling q3DISM of Cerebral Amyloid-beta Phagocytosis in Rodent Models of Alzheimer's Disease
Published on: December 26, 2016
7.9K
08:27Establishment of a Valuable Mimic of Alzheimer's Disease in Rat Animal Model by Intracerebroventricular Injection of Composited Amyloid Beta Protein
Published on: July 29, 2018
11.9K
相关概念视频
Alzheimer's Disease: Treatment
178
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
178
Alzheimer's Disease: Overview
461
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
461
Enzyme-linked Receptors
78.0K
Enzyme-linked receptors are proteins that act as both receptor and enzyme, activating multiple intracellular signals. This is a large group of receptors that include the receptor tyrosine kinase (RTK) family. Many growth factors and hormones bind to and activate the RTKs.
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...
78.0K
